REVEL trial overview
REVEL: A pivotal phase III trial in patients with metastatic NSCLC (nonsquamous or squamous histologies) with disease progression on or after platinum-based therapy (N=1253)1
A large, multinational, randomized, double-blind, placebo-controlled trial in patients with disease progression on or after one platinum-based therapy for locally advanced or metastatic disease1
REVEL TRIAL DESIGN1,2
ECOG=Eastern Cooperative Oncology Group; PS=performance status; IV=intravenous.
*Stratification factors: Geographic region, ECOG PS, prior maintenance therapy, and gender.
†24 patients at East Asian sites received a starting dose of docetaxel at 60 mg/m2 every 3 weeks.
Major Efficacy Outcome Measure: Overall survival
Supportive Efficacy Outcome Measures: Progression-free survival, objective response rate
- Patients received treatment until disease progression, unacceptable toxicity, withdrawal, or death3